Patents by Inventor Hugh D. Robertson
Hugh D. Robertson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20130085259Abstract: The invention relates to carrier complexes and methods for delivering molecules to cells. The carrier complexes comprises a molecule and an aromatic cationic peptide in accordance with the invention. In one embodiment, the method for delivering a molecule to a cell comprises contacting the cell with a carrier complex. In another embodiment, the method for delivering a molecule to a cell comprises contacting the cell with a molecule and an aromatic cationic peptide.Type: ApplicationFiled: March 16, 2012Publication date: April 4, 2013Inventors: Hazel H. Szeto, Kesheng Zhao, Hugh D. Robertson, Alex V. Birk
-
Publication number: 20100204448Abstract: The invention relates to carrier complexes and methods for delivering molecules to cells. The carrier complexes comprises a molecule and an aromatic cationic peptide in accordance with the invention. In one embodiment, the method for delivering a molecule to a cell comprises contacting the cell with a carrier complex. In another embodiment, the method for delivering a molecule to a cell comprises contacting the cell with a molecule and an aromatic cationic peptide.Type: ApplicationFiled: December 4, 2009Publication date: August 12, 2010Inventors: HAZEL H. SZETO, KESHENG ZHAO, HUGH D. ROBERTSON, ALEX V. BIRK
-
Patent number: 7704954Abstract: The invention relates to carrier complexes and methods for delivering molecules to cells. The carrier complexes comprises a molecule and an aromatic cationic peptide in accordance with the invention. In one embodiment, the method for delivering a molecule to a cell comprises contacting the cell with a carrier complex. In another embodiment, the method for delivering a molecule to a cell comprises contacting the cell with a molecule and an aromatic cationic peptide.Type: GrantFiled: May 3, 2004Date of Patent: April 27, 2010Assignee: Cornell Research Foundation, Inc.Inventors: Hazel H. Szeto, Kesheng Zhao, Hugh D. Robertson, Alex V. Birk
-
Publication number: 20030143247Abstract: A defined target for hepatitis and picornaviruses, and other viruses which utilize binding of the ribosomes to the internal ribosome entry site (“IRES”) of eukaryotic cells for viral protein translation, has been identified. Useful anti-viral compositions are compounds which block binding, physically or sterically, of the eukaryotic ribosome to the IRES to prevent translation of the viral proteins. The inhibitory molecule may bind to any ribosome subunit, initiation factor, or exposed site on the 40 S, 60 S, 48 S complex or 80 S complex in order to alter specificity of binding of the ribosome. The compounds are identified using the screening methods described herein from libraries of known compounds, including antibiotics. These compounds are then formulated for administration to a patient infected with or exposed to the virus.Type: ApplicationFiled: January 30, 2003Publication date: July 31, 2003Inventors: Hugh D. Robertson, Alita J. Lyons
-
Publication number: 20020002278Abstract: Vectors and a method for the identification of affector RNA molecules, such as ribozymes, external guide sequences, anti-sense RNA, and triple helix-forming RNA, that inhibit expression of target RNA molecules are disclosed. The method identifies functional affector RNA molecules by screening or selecting for those RNA molecules that inhibit expression of a fusion transcript, which includes the sequence of an RNA molecule of interest, from a library of potential affector RNA molecules. The vectors include a reporter gene encoding the fusion transcript including the RNA molecule of interest and RNA encoding the reporter protein. The vectors also include a second reporter gene encoding a second reporter protein. Expression of the second reporter protein can be used both to detect transformation or transfection of the vector into cells and as a control for effects on the expression of the first reporter protein that are not due to inhibition of expression of the RNA molecule of interest.Type: ApplicationFiled: November 5, 1999Publication date: January 3, 2002Inventors: TIMOTHY W. NILSEN, HUGH D. ROBERTSON, THOMAS J. KINDT
-
Patent number: 6013447Abstract: Vectors and a method for the identification of affector RNA molecules, such as ribozymes, external guide sequences, anti-sense RNA, and triple helix-forming RNA, that inhibit expression of target RNA molecules are disclosed. The method identifies functional affector RNA molecules by screening or selecting for those RNA molecules that inhibit expression of a fusion transcript, which includes the sequence of an RNA molecule of interest, from a library of potential affector RNA molecules. The vectors include a reporter gene encoding the fusion transcript including the RNA molecule of interest and RNA encoding the reporter protein. The vectors also include a second reporter gene encoding a second reporter protein. Expression of the second reporter protein can be used both to detect transformation or transfection of the vector into cells and as a control for effects on the expression of the first reporter protein that are not due to inhibition of expression of the RNA molecule of interest.Type: GrantFiled: November 21, 1997Date of Patent: January 11, 2000Assignee: Innovir Laboratories, Inc.Inventors: Timothy W. Nilsen, Hugh D. Robertson, Thomas J. Kindt
-
Patent number: 5773260Abstract: Hepatitis delta is used as a vector for inhibition of viral infection and to express proteins in vivo in a cell-specific manner. The scope of delta's use as a vector is broadened in the present invention in several important ways. For example, a delta RNA genome capable of self-replication is enlarged to carry additional information, either coding for messenger RNA for a protein, or for a targeted ribozyme, which can be delivered to liver cells using delta's normally infectious properties, or to other cell types using chimeric delta viral agents carrying altered surface proteins. In another embodiment, the delta vector is made self-limiting, so that its role in delivering targeted information is separated from its viral property of unlimited infectious replication. Targeting is achieved through the use of sequences flanking the delta sequences that have affinity for sites on RNA to be cleaved.Type: GrantFiled: June 2, 1995Date of Patent: June 30, 1998Assignee: Innovir Laboratories, Inc.Inventors: Allan R. Goldberg, Shaji T. George, Hugh D. Robertson
-
Patent number: 5763268Abstract: Hepatitis delta is used as a vector for inhibition of viral infection and to express proteins in vivo in a cell-specific manner. The scope of delta's use as a vector is broadened in the present invention in several important ways. For example, a delta RNA genome capable of self-replication is enlarged to carry additional information, either coding for messenger RNA for a protein, or for a targeted ribozyme, which can be delivered to liver cells using delta's normally infectious properties, or to other cell types using chimeric delta viral agents carrying altered surface proteins. In another embodiment, the delta vector is made self-limiting, so that its role in delivering targeted information is separated from its viral property of unlimited infectious replication. Targeting is achieved through the use of sequences flanking the delta sequences that have affinity for sites on RNA to be cleaved.Type: GrantFiled: January 9, 1995Date of Patent: June 9, 1998Assignee: Innovir Laboratories, Inc.Inventors: Allan R. Goldberg, Shaji T. George, Hugh D. Robertson
-
Patent number: 5225347Abstract: Hepatitis delta is used as a vector for inhibition of viral infection and to express proteins in vivo in a cell-specific manner. The scope of delta's use as a vector is broadened in the present invention in several important ways. For example, a delta RNA genome capable of self-replication is enlarged to carry additional information, either coding for messenger RNA for a protein, or for a targeted ribozyme, which can be delivered to liver cells using delta's normally infectious properties, or to other cell types using chimeric delta viral agents carrying altered surface proteins. In another embodiment, the delta vector is made self-limiting, so that its role in delivering targeted information is separated from its viral property of unlimited infectious replication. Targeting is achieved through the use of sequences flanking the delta sequences that have affinity for sites on RNA to be cleaved.Type: GrantFiled: March 19, 1990Date of Patent: July 6, 1993Assignee: Innovir Laboratories, Inc.Inventors: Allan R. Goldberg, Shaji T. George, Hugh D. Robertson
-
Patent number: 5225337Abstract: Ribozymes, sequences cleaving RNA, derived from sequences present in the hepatitis delta virus, have been engineered for greater specificity without increasing size. The specific ribozyme sequences are useful as reagents for cleaving RNA for experimental studies as well as antiviral therapies. Examples demonstrating the targeting of these sequences against HIV and Crohn's disease are described in detail. The sequences are also useful as diagnostics for the detection of hepatitis delta virus in tissue and fluid samples, as in blood banking, as well as in isolation and characterization of new viroids having ribozyme activity, using an RNA-specific hybridization method. Based on analysis of the two domain structure of the hepatitis delta virus, it is possible to construct a vector for expression of non-hepatitis delta virus proteins in mammalian cells.Type: GrantFiled: September 25, 1989Date of Patent: July 6, 1993Assignee: Innovir Laboratories, Inc.Inventors: Hugh D. Robertson, Allan R. Goldberg